Format

Send to

Choose Destination
Epilepsia. 2015 Jun;56(6):924-32. doi: 10.1111/epi.13008. Epub 2015 May 11.

Dose-dependent suppression of human photoparoxysmal response with the competitive AMPA/kainate receptor antagonist BGG492: Clear PK/PD relationship.

Author information

1
Child Neurology Division, Department of Pediatrics, Università "Sapienza" Roma, Rome, Italy.
2
Department of General Epileptology, Bethel Epilepsy Centre, Bielefeld, Germany.
3
Saxonian Epilepsy Center Radeberg, Radeberg, Germany.
4
Department of Neurology, Epilepsy Center Hessen - Marburg, Philipps-University, Marburg, Germany.
5
Epilepsy Center Franfurt Rhein-Main, Department of Neurology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany.
6
Neurology & Psychiatry Clinic, Wittnau, Germany.
7
Epilepsiezentrum Kork, Kehl-Kork, Germany.
8
Novartis Institutes for Biomedical Research, Basel, Switzerland.
9
Biogen Idec Inc., Cambridge, MA, U.S.A.
10
Novartis Development, Basel, Switzerland.

Abstract

OBJECTIVE:

Examine the efficacy of a competitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate glutamate receptor antagonist, selurampanel (BGG492), in the human photostimulation model.

METHODS:

Patients with epilepsy and a generalized epileptiform electroencephalography response to intermittent photic stimulation (photoparoxysmal response or PPR; diagnosed ≥ 6 months prior to initial study dosing) were enrolled in a phase II, multicenter, single-blind, within-subject, placebo-controlled proof-of-concept (PoC) study. PPR was used as a biomarker to assess the efficacy and safety of BGG492 in three cohorts (cohorts I-III received BGG492 50, 100, and 15 mg, respectively). Primary endpoints were to evaluate the efficacy of single oral BGG492 doses in abolishment of PPR or a relevant reduction of the standardized photoparoxysmal response (SPR), and to evaluate time of onset and duration of response. Secondary endpoints were to evaluate maximal SPR reduction, determine the pharmacokinetic profile of BGG492, explore the pharmacokinetic/pharmacodynamic relationship, and evaluate the safety and tolerability of BGG492.

RESULTS:

Ten patients were enrolled, with three participating twice, that is, in two cohorts (n = 13). Treatment with BGG492 resulted in abolition of PPR in seven of 13 patients in a dose-dependent manner: three, three, and one patient in cohorts I-III, respectively. All patients showed treatment-related reductions of SPR range of at least three steps in at least one eye condition (eye closure, eyes closed, or eyes open). Generally, onset of the suppressive effect appeared to be within 1-2 h post-BGG492 dose and continued in three patients at the 50- and 100-mg doses for 29-33 h. Most common adverse events across the BGG492-treated groups were headache and nasopharyngitis (three patients each), followed by dizziness, fatigue, and diarrhea (two patients each).

SIGNIFICANCE:

The dose-dependent positive effect of BGG492 on the PPR and SPR in patients with photosensitive epilepsy in this proof-of-concept study supports further investigation of AMPA receptor antagonists in large-scale phase III trials.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00784212.

KEYWORDS:

Antiepileptic drugs; BGG492; Kainate; Photoparoxysmal; Selurampanel; α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid

PMID:
25963722
DOI:
10.1111/epi.13008
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center